Robert Lechleider
Vermögen: 2 Mio $ am 31.08.2026
Vermögen: 2 Mio $ am 31.08.2026
Robert Lechleider is currently Chief Medical Officer at Immunome, Inc. since 2023.
Formerly, Dr. Lechleider was Chief Medical Officer at OncoResponse, Inc. from 2020 to 2023 and Senior Vice President-Clinical Development at Seagen, Inc. from 2016 to 2020.
Education includes undergraduate studies at Princeton University and a doctorate from the University of Illinois College of Medicine.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMMUNOME, INC. 0,06 % | 23.07.2026 | 69.805 ( 0,06 % ) | 2 Mio $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNOME, INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.10.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
OncoResponse, Inc.
OncoResponse, Inc. Pharmaceuticals: MajorHealth Technology Discovers cancer immunotherapies by interrogating the human immune system | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2023 |
| SEAGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2020 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cancer medicines | Health Technology |
Immunome, Inc.
Immunome, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which discovers, develops and commercializes antibody therapeutics | Health Technology |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois College of Medicine
University of Illinois College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoResponse, Inc.
OncoResponse, Inc. Pharmaceuticals: MajorHealth Technology Discovers cancer immunotherapies by interrogating the human immune system | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen